Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTPRB | P23467 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23736678 | 0.92 | ABCB1 (0.43) | ABCB1CYP1A2CYP2C19MEN1NPC1 | |
| SCHEMBL18929157 | 0.91 | ABCB1 (0.36) | ABCB1CYP1A2CYP2C19MEN1NPC1 | |
| SCHEMBL18928756 | 0.89 | PLA2G4A (0.34) | ABCB1 | |
| SCHEMBL20393444 | 0.88 | CYP1A2 (0.40) | ABCB1CYP1A2CYP2C19MEN1NPC1 | |
| SCHEMBL18928767 | 0.88 | ABCB1 (0.34) | ABCB1 | |
| SCHEMBL18929184 | 0.86 | ABCB1 (0.35) | ABCB1 | |
| SCHEMBL23552006 | 0.86 | ABCB1 (0.35) | ABCB1 | |
| SCHEMBL18928770 | 0.86 | ABCB1 (0.37) | ABCB1CYP1A2CYP2C19MEN1NPC1 | |
| SCHEMBL15947653 | 0.85 | ABCB1 (0.36) | ABCB1CYP1A2CYP2C19MEN1NPC1 | |
| SCHEMBL13108144 | 0.85 | ABCB1 (0.36) | ABCB1CYP1A2CYP2C19MEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872157-B1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO LTD (CN) | 2020-01-22 | — | — | EP | disclosed |
| EP-3348280-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | Hangzhou Dac Biotech Co., Ltd (CN) | 2018-07-18 | — | — | EP | disclosed |
| US-20170296663-A1 | Conjugates of Cell Binding Molecules with Cytotoxic Agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2017-10-19 | — | — | US | disclosed |
| EP-3210627-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | Hangzhou Dac Biotech Co., Ltd (CN) | 2017-08-30 | — | — | EP | disclosed |
| US-20170157262-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157262-A1 | CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS | CD4, CD2, CD47 | ABCB1 973/4885CYP1A2 4694/4885CYP2C19 4364/4885 |
| US-20170296663-A1 | Conjugates of Cell Binding Molecules with Cytotoxic Agents | CD4, CD2, CD47 | ABCB1 944/4885CYP1A2 4683/4885CYP2C19 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.